Castle Creek Pharmaceuticals has named a new executive vice president and chief development officer.
Amir Tavakkol joins the Parsippany-based company from Viamet Pharmaceuticals, where he led the antifungal drug development programs.
“We are pleased to welcome Dr. Tavakkol to the Castle Creek executive leadership team,” said Michael Derby, co-founder and CEO. “With nearly three decades of experience in drug development, his insights on designing and executing clinical trials and the regulatory review process will be especially valuable to us as we advance our pipeline of products into later stages of clinical development.”
Tavakkol has also served as senior vice president and head of clinical development and operations at Topica Pharmaceuticals, product development team leader for antifungals at Merck & Co., senior director and head of dermatology global clinical research at Schering-Plough, director and clinical program leader and associate director of medical affairs at Novartis Pharmaceuticals and senior research associate at Colgate-Palmolive Co.
“Throughout my career, I have focused on leading clinical development and medical affairs functions that have resulted in high-impact advances in the treatment of nail, skin and hair fungal diseases,” Tavakkol said. “I look forward to using my experience managing cross-functional project teams and clinical development teams in dermatology and infectious diseases to support successful regulatory filings and product launches in the exciting years ahead at Castle Creek.”
